ONC Share Price

Open 0.54 Change Price %
High 0.57 1 Day 0.01 1.79
Low 0.54 1 Week 0.00 0.00
Close 0.57 1 Month -0.03 -5.00
Volume 112035 1 Year 0.31 119.23
52 Week High 1.13
52 Week Low 0.19
ONC Important Levels
Resistance 2 0.60
Resistance 1 0.59
Pivot 0.56
Support 1 0.55
Support 2 0.54
TSE Canada Most Active Stocks
BIN 41.40 -1.62%
BIN 41.40 -1.62%
LSG 2.08 8.33%
LSG 2.08 8.33%
LSG 2.08 8.33%
TBE 0.03 0.00%
ECA 15.09 4.43%
ECA 15.09 4.43%
ECA 15.09 4.43%
SC 60.83 -0.44%
More..
TSE Canada Top Gainers Stocks
TVI 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
CUR 0.02 100.00%
PWC 0.10 25.00%
PWC 0.10 25.00%
GGA 0.06 20.00%
ANX 0.07 16.67%
ANX 0.07 16.67%
COM 2.27 14.07%
More..
TSE Canada Top Losers Stocks
GBV 0.46 -24.59%
NXJ 2.35 -10.31%
NXJ 2.35 -10.31%
RN 0.09 -10.00%
RN 0.09 -10.00%
CTU-A 0.19 -9.52%
TNP 0.90 -9.09%
TNP 0.90 -9.09%
TNX 0.34 -8.11%
QEC 0.74 -7.50%
More..

Oncolytics Biotech Inc (TSE: ONC)

ONC Technical Analysis 1.5
As on 31st Oct 2017 ONC Share Price closed @ 0.57 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.52 & Sell for SHORT-TERM with Stoploss of 0.57 we also expect STOCK to react on Following IMPORTANT LEVELS.
ONC Target for December
1st Target up-side 0.64
2nd Target up-side 0.69
3rd Target up-side 0.74
1st Target down-side 0.5
2nd Target down-side 0.45
3rd Target down-side 0.4
ONC Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.oncolyticsbiotech.com
ONC Address
ONC
1167 Kensington Crescent NW
Suite 210
Calgary, AB T2N 1X7
Canada
Phone: 403-670-7377
Fax: 403-283-0858
ONC Latest News
Interactive Technical Analysis Chart Oncolytics Biotech Inc ( ONC TSE Canada )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Oncolytics Biotech Inc
ONC Business Profile
Oncolytics Biotech Inc., a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancers. The company develops REOLYSIN, a therapeutic reovirus that is in various clinical trials for use as human cancer therapeutic. Its cancer product is a potential therapeutic for tumours possessing an activated Ras pathway. The company was founded in 1998 and is headquartered in Calgary, Canada.